Back

Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Novel therapeutic targets in hypertrophic cardiomyopathy Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Andrew Wang

Duke University Medical Center, Durham (United States of America)

4 More presentations in this session

Presentation thumbnail
State of the Art in the treatment of hypertrophic cardiomyopathy
Professor I. Olivotto (Florence, IT)
Slides Video
Presentation thumbnail
Earlier surgical myectomy vs. waiting for a Class I indication is associated with improved long-term survival in symptomatic hypertrophic obstructive cardiomyopathy patients
Doctor M. Desai (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
A novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)
Doctor G. Norrish (London, GB)
Abstract Slides Video
Presentation thumbnail
Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis.
Professor J. Veselka (Prague, CZ)
Slides Video

Access the full session

Session thumbnail
Novel therapeutic targets in hypertrophic cardiomyopathy

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources